These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2427003)

  • 1. Disopyramide: clinical indications, pharmacokinetics and laboratory assessment.
    Taylor EH; Pappas AA
    Ann Clin Lab Sci; 1986; 16(4):289-95. PubMed ID: 2427003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetic and pharmacodynamic effects of varying the free fraction of disopyramide.
    Shaw LM; Doherty JU; Waxman HL; Josephson ME
    Angiology; 1987 Feb; 38(2 Pt 2):192-7. PubMed ID: 3826754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disopyramide: a review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias.
    Heel RC; Brogden RN; Speight TM; Avery GS
    Drugs; 1978 May; 15(5):331-68. PubMed ID: 350555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of phenytoin on serum disopyramide concentrations.
    Nightingale J; Nappi JM
    Clin Pharm; 1987 Jan; 6(1):46-50. PubMed ID: 3816106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antiarrhythmic treatment of ventricular ectropic arrhythmies with Disopyramide].
    Olbermann M; Just H; Guckenbiehl H; Lang KF
    Med Klin; 1976 Apr; 71(14):593-8. PubMed ID: 57567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disopyramide-induced ventricular tachycardia.
    Lo KS; Gantz KB; Stetson PL; Lucchesi BR; Pitt B
    Arch Intern Med; 1980 Mar; 140(3):413-4. PubMed ID: 6153888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative study of quinidine and disopyramide in the treatment of stable ventricular extrasystole].
    Barnay C; Medvedowsky JL; Clémenty J; Bricaud H; Pellet J; Denis B; Machecourt J; Wolf JE; Dimitrio R; Egre A
    Arch Mal Coeur Vaiss; 1983 Aug; 76(8):909-17. PubMed ID: 6194768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of disopyramide.
    Siddoway LA; Woosley RL
    Clin Pharmacokinet; 1986; 11(3):214-22. PubMed ID: 3524956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics of disopyramide in patients with acute myocardial infarction.
    Jounela AJ; Pentikäinen PJ; Oksanen K
    Int J Clin Pharmacol Ther Toxicol; 1982 Jun; 20(6):276-82. PubMed ID: 7107076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog.
    Karim A; Kook C; Novotney RL; Zagarella J; Campion J
    Drug Metab Dispos; 1978; 6(3):338-45. PubMed ID: 26556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.
    Lima JJ; Boudoulas H; Blanford M
    J Pharmacol Exp Ther; 1981 Dec; 219(3):741-7. PubMed ID: 7299695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of free disopyramide plasma concentrations using ultrafiltration and enzyme multiplied immunoassay.
    Raghow G; Meyer MC; Straughn AB
    Ther Drug Monit; 1985; 7(4):466-71. PubMed ID: 3909539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applicability of capillary gas liquid chromatography to the measurement of free fraction of disopyramide in human plasma.
    Kapil RP; Axelson JE; Lalka D; Edwards DJ; Kerr CR
    Res Commun Chem Pathol Pharmacol; 1985 Apr; 48(1):153-6. PubMed ID: 3992030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical scope of disopyramide seven years after introduction--an overview.
    Willis PW
    Angiology; 1987 Feb; 38(2 Pt 2):165-73. PubMed ID: 2435196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disopyramide analysis using REMEDi: comparison with EMIT and conventional high performance liquid chromatographic methods.
    Patel V; McCarthy PT; Flanagan RJ
    Biomed Chromatogr; 1991 Nov; 5(6):269-72. PubMed ID: 1760593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of disopyramide pharmacokinetics with efficacy in ventricular tachyarrhythmia.
    Rangno RE; Warnica W; Ogilvie RI; Kreeft J; Bridger E
    J Int Med Res; 1976; 4(1 Suppl):54-8. PubMed ID: 1026530
    [No Abstract]   [Full Text] [Related]  

  • 17. Intravenous disopyramide in acute myocardial infarction: a haemodynamic and pharmacokinetic study.
    Cameron J; Stafford W; Pritchard D; Norris R; Ravenscroft P
    J Cardiovasc Pharmacol; 1984; 6(1):126-31. PubMed ID: 6199595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anticholinergic side effects of disopyramide and controlled-release disopyramide.
    Teichman S
    Angiology; 1985 Nov; 36(11):767-71. PubMed ID: 4061965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors affecting the binding of disopyramide to serum proteins.
    Shaw LM; Altman R; Thompson BC; Fields L
    Clin Chem; 1985 Apr; 31(4):616-9. PubMed ID: 3884182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between the therapeutic effects or side-effects and the serum disopyramide or mono-N-dealkylated disopyramide concentration after repeated oral administration of disopyramide to arrhythmic patients.
    Masuhara K; Ohno T; Hamaguchi K; Katoh K; Kashiwada K; Takahashi S; Tanaka Y; Someya K; Ogata H
    Int J Clin Pharmacol Res; 1995; 15(3):103-13. PubMed ID: 8847151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.